Effets secondaires des inhibiteurs de tyrosine kinase dans la leucémie myéloïde chronique [Recognizing and managing side effects of tyrosine kinase inhibitors in chronic myeloid leukemia]
Fiche du document
15 novembre 2023
- doi: 10.53738/REVMED.2023.19.850.2175
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.850.2175
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37966150
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_8CD75E04E5AE2
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-05-15 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
TherapyCiter ce document
J. Dereme et al., « Effets secondaires des inhibiteurs de tyrosine kinase dans la leucémie myéloïde chronique [Recognizing and managing side effects of tyrosine kinase inhibitors in chronic myeloid leukemia] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.850.2175
Métriques
Partage / Export
Résumé
Tyrosine kinase inhibitors (TKI) have emerged as a paradigm-shifting therapeutic approach for the treatment of chronic myeloid leukemia (CML) following their regulatory approval in 2001. These agents have revolutionized the management of CML by significantly improving patient outcomes and enabling them to achieve near-normal life expectancies. Consequently, the utilization of TKI has become increasingly prevalent, accompanied by the recognition and management of their associated adverse effects. Given the expanding patient population receiving TKI therapy, it is imperative that hematologists, as well as general practitioners, assume the responsibility of closely and meticulously monitoring patients' treatment progress while effectively addressing the occurrence of any untoward effects.